Latest News

Tirzepatide Cuts Cardiometabolic Risk in OSA, Obesity
Written by: Radcliffe CVRM
Tirzepatide Cuts Cardiometabolic Risk in OSA, Obesity
Metabolite Profile Predicts Future Type 2 Diabetes Risk
Written by: Radcliffe CVRM
Metabolite Profile Predicts Future Type 2 Diabetes Risk
New Horizons in Dyslipidaemia 2026
Written by: Radcliffe CVRM
New Horizons in Dyslipidaemia 2026
SELECT: Semaglutide Reduces Hospital Admissions
Written by: Radcliffe CVRM
SELECT: Semaglutide Reduces Hospital Admissions
High-Dose Flu Vaccine Reduces Hospitalisation in CKD
Written by: Radcliffe CVRM
High-Dose Flu Vaccine Reduces Hospitalisation in CKD
Metabolic Factors Now Key Drivers of Heart Failure
Written by: Radcliffe Cardiology
Metabolic Factors Now Key Drivers of Heart Failure
Global Economic Burden of Diabetes to Exceed $10 Trillion
Written by: Radcliffe CVRM
Global Economic Burden of Diabetes to Exceed $10 Trillion
Metabolome-Informed BMI Better Predicts CVRM Risk
Written by: Radcliffe CVRM
Metabolome-Informed BMI Better Predicts CVRM Risk
Tirzepatide Noninferior to Dulaglutide for CV Events
Written by: Radcliffe CVRM
Tirzepatide Noninferior to Dulaglutide for CV Events
Oral Orforglipron Aids Weight Loss in Type 2 Diabetes
Written by: Radcliffe CVRM
Oral Orforglipron Aids Weight Loss in Type 2 Diabetes

External news

Written by: Cardiovascular Business
Medtronic’s newest all-in-one PFA catheter gains critical approval
Written by: Medscape
Jan 23 2026 This Week in Cardiology
Written by: Cardiovascular Business
Vascular surgeon accused of double murder pleads not guilty
Written by: Medscape
Early Cholesterol Treatment May Lower Lifetime Heart Risk
Written by: Cardiovascular Business
CVRx hopes new research will expand access to heart failure therapy
Written by: Medscape
Conference MDAngle: ISC 2026 Post-Stroke Care
Written by: Medscape
ISC 2026: Previewing Advances in Post-Stroke Care
Written by: heart.org - Heart news
Hot tips for cold weather heart health
Written by: Cardiac Vascular News
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES
Written by: Cardiovascular Business
IVL competition heats up as Boston Scientific enters US market